MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
| Autor: | Silke Hausberger, Stefan Palkovits, Laura Pertl, Anton Haas, Gerald Seidel, Johanna Makk, Christoph Singer, Martin Weger, Eva Maria Malle, Julia Osterholt, Sereina A. Herzog |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Time Factors genetic structures Bevacizumab Fundus Oculi Visual Acuity Angiogenesis Inhibitors Drug Administration Schedule Screening Examination 03 medical and health sciences 0302 clinical medicine Optical coherence tomography Interquartile range Ophthalmology medicine Humans Macula Lutea Prospective Studies Fluorescein Angiography Intravitreal bevacizumab Aged Aged 80 and over Dose-Response Relationship Drug medicine.diagnostic_test Choroid business.industry Organ Size General Medicine Middle Aged Macular degeneration medicine.disease Exudative age-related macular degeneration Response to treatment eye diseases Receptors Vascular Endothelial Growth Factor Treatment Outcome 030104 developmental biology Intravitreal Injections Wet Macular Degeneration 030221 ophthalmology & optometry sense organs business Tomography Optical Coherence Follow-Up Studies medicine.drug |
| Zdroj: | Retina. 37:2262-2268 |
| ISSN: | 0275-004X |
| Popis: | To evaluate the effect of intravitreal bevacizumab on the macular choroidal volume and the subfoveal choroidal thickness in treatment naive eyes with exudative age-related macular degeneration. The macular choroidal volume and the subfoveal choroidal thickness were measured using enhanced depth imaging optical coherence tomography. After a screening examination, each patient received 3 monthly intravitreal injections of 1.25 mg bevacizumab. One month after the third injection was a final assessment. Forty-seven patients with a mean age of 80 ± 6.4 years were included. The macular choroidal volume decreased significantly from median 4.1 mm3 (interquartile range 3.4–5.9) to median 3.9 mm3 (interquartile range 3.1–5.6) between the baseline and final examination (difference −0.46 mm3, 95% confidence interval: −0.57 to 0.35, P < 0.001). Similarly, subfoveal choroidal thickness had decreased from 157.0 μm (interquartile range 116.0–244.5) at baseline to 139.0 μm (interquartile range 102.5–212.0) at the final examination (P < 0.001). Both parameters macular choroidal volume at baseline and subfoveal choroidal thickness at baseline were not associated with the response to treatment. The macular choroidal volume and the subfoveal choroidal thickness decreased significantly after 3 monthly bevacizumab injections for exudative age-related macular degeneration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|